Poseida therapeutics presents new case study demonstrating reactivation of car-t therapy with a t-cell engager in a patient with relapsed multiple myeloma

Reactivation of p-bcma-101 car-t cells and a repeat stringent complete response (scr) more than 3 years after original car-t therapy demonstrates potential of stem cell memory t cells (tscm), a key differentiator for poseida's car-t programs  san diego , sept. 4, 2024 /prnewswire/ -- poseida therapeutics, inc. (nasdaq: pstx), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, highlighted new data from a case study of a patient with relapsed multiple myeloma treated in a clinical trial of p-bcma-101, the company's original investigational t stem cell memory (tscm)-rich bcma targeting autologous car-t cell therapy.
CAR Ratings Summary
CAR Quant Ranking